CEL 1000

Drug Profile

CEL 1000

Alternative Names: CEL-1000; CEL-1000 peptide; derG; DGQEEKAGVVSTGLIGGG

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; National Institute of Allergy and Infectious Diseases; Naval Medical Research Center; United States Army Medical Research Institute of Infectious Diseases; University of Arkansas System; University of Nebraska Medical Center
  • Class Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Eastern equine encephalomyelitis; Hepatitis B; Herpes simplex virus infections; Influenza A virus H5N1 subtype; Malaria; Severe acute respiratory syndrome; Smallpox; Vaccinia; Venezuelan equine encephalomyelitis; West Nile virus infections; Western equine encephalitis virus infections
  • Discontinued Chlamydial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Encephalitis-virus-infections in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in USA (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top